CLINICAL AND HISTOLOGIC RATING OF TREATMENT WITH ACEFYLLINATE OF AMBROXOL IN PATIENTS WITH CHRONIC-BRONCHITIS

This randomized, double-blind, placebo-controlled trial rated the safe ty and anti-inflammatory activity of treatment with acefyllinate of am broxol in patients with Stable chronic bronchitis. Twenty men with a f orced expiratory volume in 1 second of 57% received active drug or pla cebo for 3 weeks. Antiinflammatory efficacy was determined by means of specific clinical symptoms and histologic analysis of biopsy specimen s obtained during bronchoscopy at the beginning and end of treatment. Patients treated with acefyllinate of ambroxol showed clear-cut improv ement in all symptoms and reported no side effects. Histologic analysi s was confirmatory: Statistically significant morphologic improvement versus placebo (P<.05) was noted in subsidence of inflammation, decrea se in hyperplasia of the basal layer cells, and revival of the epithel ium. Acefyllinate of ambroxol is an effective agent that can be used a s basic monotherapy in the management of chronic bronchitis.